Hc Advisors, LLC Akebia Therapeutics, Inc. Transaction History

Hc Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.3 - $0.46 $3,000 - $4,600	10,000 New	10,000 $3,000
Q1 2021 May 07, 2021	SELL	$2.92 - $5.06 $40,880 - $70,840	-14,000 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$2.22 - $3.78 $5,303 - $9,030	-2,389 Reduced 14.58%	14,000 $39,000
Q3 2020 Nov 04, 2020	BUY	$2.39 - $13.08 $39,169 - $214,368	16,389 New	16,389 $41,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Hc Advisors, LLC with notifications on news.